Citation Impact
Citing Papers
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
2001 StandoutScienceNobel
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF
2001 StandoutScience
Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe
1996
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
2007 StandoutNobel
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
2010 StandoutNobel
Hypoxia and intra-complex genetic suppressors rescue complex I mutants by a shared mechanism
2024 StandoutNobel
Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells
2011 StandoutNobel
Rac1 Activity Is Required for the Activation of Hypoxia-inducible Factor 1
2001 StandoutNobel
Suppression of tumor growth through disruption of hypoxia-inducible transcription
2000 StandoutNobel
C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation
2001 StandoutNobel
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
2007 StandoutNobel
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex
2001 StandoutNobel
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
The pressure rises: update on the genetics of phaeochromocytoma
2002
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Cushing's syndrome
2015 Standout
Hypoxia and Inflammation
2011 Standout
Hereditary paraganglioma targets diverse paraganglia: Table 1
2002
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases
2007
LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE CARCINOMA
1998
Oxygen sensing by HIF hydroxylases
2004 StandoutNobel
DNp73 Exerts Function in Metastasis Initiation by Disconnecting the Inhibitory Role of EPLIN on IGF1R-AKT/STAT3 Signaling
2013
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
2002 StandoutNobel
The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells
2006
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
2001
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation
2003 Standout
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
2006 StandoutNobel
Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases
2008
Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies
2006
Does radioiodine therapy have disadvantageous effects in non‐iodine accumulating differentiated thyroid carcinoma?
2002
Selection of Mutant CHO Cells with Constitutive Activation of the HIF System and Inactivation of the von Hippel-Lindau Tumor Suppressor
2001 StandoutNobel
Sporadic Pheochromocytomas Are Rarely Associated with Germline Mutations in thevhlTumor Suppressor Gene or theretProtooncogene1
1997
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
2008 StandoutNobel
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation
2001 StandoutNobel
FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity
2001 StandoutNobel
Management of Well-Differentiated Thyroid Cancer in 2010: Perspectives of a Head and Neck Surgical Oncologist
2010
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
2000 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
p73: Friend or foe in tumorigenesis
2002
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells
2003
Sequential Follow-up of Serum Thyroglobulin and Whole Body Scan in Thyroid Cancer Patients without Initial Metastasis
2006
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Accumulation of the FACT complex, as well as histone H3.3, serves as a target marker for somatic hypermutation
2013 StandoutNobel
Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies
2005
Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid Cancer
2007
von Hippel-Lindau Disease
2006 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
PROLINE HYDROXYLATION AND GENE EXPRESSION
2005 StandoutNobel
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma
2008
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
2002 StandoutScienceNobel
Survival and Therapeutic Modalities in Patients with Bone Metastases of Differentiated Thyroid Carcinomas
2001
Reoperative Thyroid Surgery
1997
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma
1998
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
2013 StandoutScience
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
2005
Prognostic Significance of the Number of Metastatic Lymph Nodes to Stratify the Risk of Recurrence
2013
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
The Molecular Basis of Von Hippel-Lindau Disease
1997 StandoutNobel
Works of A. Frilling being referenced
Growth Regulation of Normal Thyroids and Thyroid Tumors in Man
1990
A new therapeutic approach in medullary thyroid cancer treatment: Inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant
2002
Liver Transplantation for Metastatic Carcinoid Tumors
1994
VEGF is Important for Early Liver Regeneration After Partial Hepatectomy
2007
[Indications for and basic principles of the surgical treatment of thyroid diseases].
1989
Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease.
1996
Surgical reintervention for differentiated thyroid cancer
1993
Transactivation-deficient DeltaTA-p73 acts as an oncogene.
2002
Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
1996
Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
2003